Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial

NCT: NCT03820947 · TERMINATED

NCT IDNCT03820947
StatusTERMINATED
Start Date2020-02-05
Completion2025-11-10
SponsorMedtronic Endovascular (INDUSTRY)
First posted
Last updated

Brief Summary

Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease

Frequently Asked Questions

What is VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial?

VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial is a clinical trial registered under NCT03820947. Current status: TERMINATED.

What is the status of NCT03820947?

The current status of NCT03820947 (VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial) is: TERMINATED.

When did VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial start?

VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial started on 2020-02-05.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑